NMT2

Across TCGA pan-cancer cohorts, NMT2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NMT2 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher NMT2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NMT2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LSCC, UCEC, and CCRCC are the cancer types where NMT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	III,IV	0.413	0.938	.002	33	view →
UCEC	OS	Median	III,IV	0.433	1.000	.007	28	view →
CCRCC	DFS	Median	III,IV	0.960	0.766	.013	9	view →
LUAD	DFS	Median	III,IV	0.315	0.948	.008	6	view →
HNSC	DFS	Median	IV	0.565	0.745	.024	4	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NMT2–LSCC (DFS)

Open the LSCC breakdown →